210 related articles for article (PubMed ID: 27108935)
1. The muscarinic antagonists scopolamine and atropine are competitive antagonists at 5-HT3 receptors.
Lochner M; Thompson AJ
Neuropharmacology; 2016 Sep; 108():220-8. PubMed ID: 27108935
[TBL] [Abstract][Full Text] [Related]
2. The antimalarial drug proguanil is an antagonist at 5-HT3 receptors.
Lochner M; Thompson AJ
J Pharmacol Exp Ther; 2014 Dec; 351(3):674-84. PubMed ID: 25277140
[TBL] [Abstract][Full Text] [Related]
3. Mapping the Orthosteric Binding Site of the Human 5-HT
Jack T; Leuenberger M; Ruepp MD; Vernekar SKV; Thompson AJ; Braga-Lagache S; Heller M; Lochner M
ACS Chem Neurosci; 2019 Jan; 10(1):438-450. PubMed ID: 30149702
[TBL] [Abstract][Full Text] [Related]
4. Noncompetitive Inhibition of 5-HT3 Receptors by Citral, Linalool, and Eucalyptol Revealed by Nonlinear Mixed-Effects Modeling.
Jarvis GE; Barbosa R; Thompson AJ
J Pharmacol Exp Ther; 2016 Mar; 356(3):549-62. PubMed ID: 26669427
[TBL] [Abstract][Full Text] [Related]
5. Ginkgolide B and bilobalide block the pore of the 5-HT₃receptor at a location that overlaps the picrotoxin binding site.
Thompson AJ; Jarvis GE; Duke RK; Johnston GA; Lummis SC
Neuropharmacology; 2011; 60(2-3):488-95. PubMed ID: 21059362
[TBL] [Abstract][Full Text] [Related]
6. Menthol inhibits 5-HT3 receptor-mediated currents.
Ashoor A; Nordman JC; Veltri D; Yang KH; Shuba Y; Al Kury L; Sadek B; Howarth FC; Shehu A; Kabbani N; Oz M
J Pharmacol Exp Ther; 2013 Nov; 347(2):398-409. PubMed ID: 23965380
[TBL] [Abstract][Full Text] [Related]
7. The antimalarial drugs quinine, chloroquine and mefloquine are antagonists at 5-HT3 receptors.
Thompson AJ; Lochner M; Lummis SC
Br J Pharmacol; 2007 Jul; 151(5):666-77. PubMed ID: 17502851
[TBL] [Abstract][Full Text] [Related]
8. "Methylene Bridge" to 5-HT
Abdelkhalek AS; Alley GS; Alwassil OI; Khatri S; Mosier PD; Nyce HL; White MM; Schulte MK; Dukat M
ACS Chem Neurosci; 2019 Mar; 10(3):1380-1389. PubMed ID: 30375852
[TBL] [Abstract][Full Text] [Related]
9. The multimodal antidepressant vortioxetine may facilitate pyramidal cell firing by inhibition of 5-HT
Dale E; Grunnet M; Pehrson AL; Frederiksen K; Larsen PH; Nielsen J; Stensbøl TB; Ebert B; Yin H; Lu D; Liu H; Jensen TN; Yang CR; Sanchez C
Brain Res; 2018 Jun; 1689():1-11. PubMed ID: 29274875
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the receptor selectivity of the H3 receptor antagonists, iodophenpropit and thioperamide: an interaction with the 5-HT3 receptor revealed.
Leurs R; Tulp MT; Menge WM; Adolfs MJ; Zuiderveld OP; Timmerman H
Br J Pharmacol; 1995 Oct; 116(4):2315-21. PubMed ID: 8564266
[TBL] [Abstract][Full Text] [Related]
11. Mode of action of gingerols and shogaols on 5-HT3 receptors: binding studies, cation uptake by the receptor channel and contraction of isolated guinea-pig ileum.
Abdel-Aziz H; Windeck T; Ploch M; Verspohl EJ
Eur J Pharmacol; 2006 Jan; 530(1-2):136-43. PubMed ID: 16364290
[TBL] [Abstract][Full Text] [Related]
12. Bupropion Inhibits Serotonin Type 3AB Heteromeric Channels at Clinically Relevant Concentrations.
Stuebler AG; Jansen M
Mol Pharmacol; 2020 Mar; 97(3):171-179. PubMed ID: 31871303
[TBL] [Abstract][Full Text] [Related]
13. Conformational Changes in the 5-HT
Munro L; Ladefoged LK; Padmanathan V; Andersen S; Schiøtt B; Kristensen AS
Mol Pharmacol; 2019 Dec; 96(6):720-734. PubMed ID: 31582575
[TBL] [Abstract][Full Text] [Related]
14. The nonpsychoactive cannabinoid cannabidiol inhibits 5-hydroxytryptamine3A receptor-mediated currents in Xenopus laevis oocytes.
Yang KH; Galadari S; Isaev D; Petroianu G; Shippenberg TS; Oz M
J Pharmacol Exp Ther; 2010 May; 333(2):547-54. PubMed ID: 20160007
[TBL] [Abstract][Full Text] [Related]
15. The antidepressant bupropion is a negative allosteric modulator of serotonin type 3A receptors.
Pandhare A; Pappu AS; Wilms H; Blanton MP; Jansen M
Neuropharmacology; 2017 Feb; 113(Pt A):89-99. PubMed ID: 27671323
[TBL] [Abstract][Full Text] [Related]
16. The binding characteristics and orientation of a novel radioligand with distinct properties at 5-HT3A and 5-HT3AB receptors.
Thompson AJ; Verheij MH; Verbeek J; Windhorst AD; de Esch IJ; Lummis SC
Neuropharmacology; 2014 Nov; 86():378-88. PubMed ID: 25174552
[TBL] [Abstract][Full Text] [Related]
17. VUF10166, a novel compound with differing activities at 5-HT₃A and 5-HT₃AB receptors.
Thompson AJ; Verheij MH; de Esch IJ; Lummis SC
J Pharmacol Exp Ther; 2012 May; 341(2):350-9. PubMed ID: 22306960
[TBL] [Abstract][Full Text] [Related]
18. Common discriminative stimulus properties in rats of muscarinic antagonists, clozapine and the D3 preferring antagonist PNU-99194a: an analysis of possible mechanisms.
Goudie AJ; Baker LE; Smith JA; Prus AJ; Svensson KA; Cortes-Burgos LA; Wong EH; Haadsma-Svensson S
Behav Pharmacol; 2001 Sep; 12(5):303-15. PubMed ID: 11710745
[TBL] [Abstract][Full Text] [Related]
19. Agonists and antagonists bind to an A-A interface in the heteromeric 5-HT3AB receptor.
Lochner M; Lummis SC
Biophys J; 2010 Apr; 98(8):1494-502. PubMed ID: 20409468
[TBL] [Abstract][Full Text] [Related]
20. Competitive antagonism of the mouse 5-hydroxytryptamine3 receptor by bisindolylmaleimide I, a "selective" protein kinase C inhibitor.
Coultrap SJ; Sun H; Tenner TE; Machu TK
J Pharmacol Exp Ther; 1999 Jul; 290(1):76-82. PubMed ID: 10381762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
